Wikipedia -WSS

Wikipedia

author：comprehensive 2025-10-01 15:30:50 - browse：143

Sarepta - Cambridge -AP — A logo sign outside of the headquarters of Sarepta Therapeutics in Cambridge, Mass. Kristoffer Tripplaar/Sipa via AP

Reviewers at the Food and Drug Administration were leaning toward rejecting a closely watched gene therapy for Duchenne muscular dystrophy made by Sarepta Therapeutics, prompting a top official to intervene earlier this year, according to three people with direct knowledge of the agency deliberations.

Inside the FDA office that oversees gene therapies, some staff had reached a non-binding conclusion that Sarepta’s gene therapy should be rejected, the individuals said, speaking on condition of anonymity. Peter Marks, a top FDA official and vocal advocate for faster gene therapy approvals, stepped in and directed staff to schedule a public hearing on the therapy on May 12.

Sarepta announced the scheduling of the public hearing last month, but the internal deliberations that led to it have not been previously reported.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Seattle police shoot person suspected in downtown stabbing

WSS

Seattle police shoot person suspected in downtown stabbing

In areas with more Black doctors, Black people live longer

The battle over the Brookhaven Landfill on Long Island

Disclosing genetic information: not as worrisome as once feared

New warning issued for rebooking air travel after delays, cancellations

Man who had jail sentence commuted by Trump arrested again

leisure time

Wikipedia

knowledge

The high cost of giving birth even with insurance

CDC concerned about possible undetected monkeypox spread in U.K.

New air purifier tech could be key to improving indoor air quality

Plane’s emergency slide plummets from sky, hits Chicago home

Medical records are filled with copy

Why drug prescriptions should include diagnoses

BioMarin wins approval for gene therapy to treat hemophilia A

Colonoscopy at 40? Study finds a possible benefit

23andMe had bad news about my health. I wish a person had delivered it

Trump got a 'target letter.' What is one and what does it mean?

focus

Stanford president to resign after investigation of research

Why the Crimean Bridge is key to Russia's war in Ukraine

Celebrate National Dole Whip Day for 3 days this week at Disney

States increasingly look to regulate hospital facility fees

The story of mRNA: From a loose idea to a tool that may help curb Covid

'Reaching a detente': STAT's Helen Branswell on covering Covid

hotspot

leisure time

focus

focus